Drug Trial Radar · NCT01828957
Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants
Last checked: Nov 20, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
69
Actual
Start
Apr 2013
Primary completion
May 2015
Study completion Aug 2015
Sponsor
- Lead sponsor
- Medipost Co Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 days, up to 14 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the efficacy and safety of a single intratracheal administration of Pneumostem® for treatment of Bronchopulmonary Dysplasia (BPD) in high-risk premature infants by comparing Pneumostem-treated group with a control group.
Conditions
- Bronchopulmonary Dysplasia
Interventions
Pneumostem®Biological
Normal SalineOther
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of BPD (moderate to severe) or mortality at 36 weeks PMATime frame: 36 weeks PMA
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.